Please login to the form below

Not currently logged in
Email:
Password:

CD3

This page shows the latest CD3 news and features for those working in and with pharma, biotech and healthcare.

Amgen pledges $1.5bn for CytomX preclinical cancer drugs

Amgen pledges $1.5bn for CytomX preclinical cancer drugs

bispecific) antibody targeting the epidermal growth factor receptor (EGFR) and CD3 receptor that has come out of CytomX’s Probody platform. ... CytomX will handle the early stages of clinical development of the EGFR/CD3 Probody, with Amgen getting

Latest news

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Taking a lean and careful approach Taking a lean and careful approach

    Its fully human engineered CD3 antibody Foralumab has reached phase II with potential for a wide range of autoimmune and inflammatory diseases such as non-alcoholic steatohepatitis (NASH), primary biliary cholangitis,

  • Deal Watch June 2016 Deal Watch June 2016

    Both antibodies have a cytotoxic T-cell binding domain (CD3), which activates T-cells at the site of the tumour for killing of malignant cells, and a specific tumour antigen binding

  • Pharma deals during December 2014 Pharma deals during December 2014

    platform. The antibody targets both CD19 and CD3 and is being developed for the treatment of B-cell malignancies.

  • Deal Watch table for August 2014 Deal Watch table for August 2014

    187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).

  • Pharma deals during February 2014 Pharma deals during February 2014

    CD123 and CD3.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Redline Strategic

We are a healthcare consultancy, specialising in people and experiences. Using innovative research methods to capture the thoughts of real...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics